Year: 2014
Type: article
Abstract: INTRODUCTION: Alzheimer's disease (AD) is characterized by the accumulation of β-amyloid (Aβ) associated with brain atrophy and cognitive decline. The functional form to model the association between Aβ and regional brain atrophy has not been well defined. To determine the relationship between Aβ and atrophy, we compared the performance of the usual dichotomization of cerebrospinal fluid (CSF) Aβ to identify subjects as Aβ+ and Aβ- with a trilinear spline model of CSF Aβ. METHODS: One hundred and eighty-three subjects with mild cognitive impairment and 108 cognitively normal controls with baseline CSF Aβ and up to 4 years of longitudinal magnetic resonance imaging data from the Alzheimer's Disease Neuroimaging Initiative were analyzed using mixed-effects regression. Piecewise-linear splines were used to evaluate the nonlinear nature of the association between CSF Aβ and regional atrophy and to identify points of acceleration of atrophy with respect to Aβ. Several parameterizations of CSF Aβ were compared using likelihood ratio tests and the Akaike information criterion. Periods of acceleration of atrophy in which subjects transition from CSF Aβ negativity to CSF Aβ positivity were estimated from the spline models and tested for significance. RESULTS: Spline models resulted in better fits for many temporal and parietal regions compared with the dichotomous models. The trilinear model showed that periods of acceleration of atrophy varied greatly by region with early changes seen in the insula, amygdala, precuneus, hippocampus, and other temporal regions, occurring before the clinical threshold for CSF Aβ positivity. DISCUSSION: The use of piecewise-linear splines provides an improved model of the nonlinear association between CSF Aβ and regional atrophy in regions implicated in the progression of AD. The important biological finding of this work is that some brain regions show periods of accelerated volume loss well before the CSF Aβ42 threshold. This implies that signs of brain atrophy develop before the current conventional definition of "preclinical AD".
Source: Alzheimer s & Dementia
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: Alzheimer's disease, amyloid-beta
Open Access status: bronze
Funders: Alzheimer's Association, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Merck, Novartis, Biogen, University of Pennsylvania, Mayo Foundation for Medical Education and Research, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Eisai, Tohoku University, National Institutes of Health, Genentech, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Mental Health, National Institute of Biomedical Imaging and Bioengineering
Awards: G1129981694, UC Davis Alzheimer's Disease Core Center, G2835601961, G29951154, A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease, G3146424788, G3638781909, G3870774570, "MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies", Cognitive and Neuroimaging Predictors of Disability in Late Life Depression, Alzheimer's Disease Core Center, Alzheimer's Disease Cooperative Study (ADCS), Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers, Alzheimer's Disease Neuroimaging Initiative, G5830250196, ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5, VITAMIN E TRIAL IN PERSONS WITH DOWN SYNDROME, Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Dominantly Inherited Alzheimer Network, Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system, G9000122335, G9000239186, G9000338148, Characterizing Cognitive Decline in Late Life Depression: The ADNI-D Project
OpenAlex ID: W2148943235
